Non-formulary methylphenidate ER (Quillivant XR®) will be covered on the prescription drug benefit when the following criteria are met:

- Diagnosis of ADHD or ADD
  -AND-

1) For patients under age 21:
   - Patient has documented intolerance or contraindication to sprinkle formulations and is unable to swallow whole tablets
   -OR-
   - Patient is already stable on the drug

2) For patients 21 years of age not currently taking Quillivant XR:
   - Adequate trial** (7 days) of methylphenidate ER (Metadate CD) or methylphenidate ER (Ritalin LA), unless allergy to an inactive ingredient
     -AND-
   - Adequate trial** (7 days) of methylphenidate ER (Concerta) (must have at least partial response), unless allergy to an inactive ingredient

3) For patients currently taking Quillivant XR:
   - Adequate trial** (7 days) of methylphenidate ER (Metadate CD) or methylphenidate ER (Ritalin LA), unless allergy to an inactive ingredient or currently taking methylphenidate ER (Quillivant XR) with an antipsychotic or mood stabilizer (lithium or an antiepileptic drug used for mood stabilization)
     -AND-
   - Adequate trial** (7 days) of methylphenidate ER (Concerta) (must have at least partial response), unless allergy to an inactive ingredient or currently taking methylphenidate ER (Quillivant XR) with an antipsychotic or mood stabilizer (lithium or an antiepileptic drug used for mood stabilization)
     -OR-
   - Dose change only: patient meets current criteria and is already taking the drug

** Adequate trial of a long acting agent is further defined as wearing off that is not resolved by increasing the dose, AND adding a short-acting agent OR increasing frequency to twice daily OR clinically significant side effects related to the dosage form that cannot be resolved by adjusting the dose or timing.